The Center for U.S.-Mexican Studies at the University of California San Diego released preliminary findings from its groundbreaking cross-border education study, which provides insight into the educational aspirations and professional trajectories of young people in San Diego and Tijuana.
IBM's World Community Grid and scientists from Brazil, the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, and Rutgers New Jersey Medical School have launched OpenZika, a project to find drug candidates to treat Zika, a fast spreading virus that the World Health Organization has declared a global public health emergency.
“Mass Effect: New Earth, A 4D Holographic Journey” opens to the public today and features Near/Far Acoustic Field (NFAF), an audio infrastructure developed by researchers based at the Qualcomm Institute.
The unorthodox historian and journalist, Tom Segev, has been intrepid in exploring and illuminating the tortured history of Israel and the Holocaust, often exposing painful truths that many would rather not have to grapple with. Born in Jerusalem to parents who fled Nazi Germany, Segev is a leading figure among the so-called “New Historians” of Israel, who have continued to challenge many of the nation’s traditional narratives or “founding myths.”
The University of California San Diego’s Division of Arts and Humanities significantly increased its presence on the recently released list of 2016 – 2017 Hellman Fellowships, a university program designed to provide financial support to promising faculty for activities that enhance progress toward tenure. Last year’s divisional recipients included an associate professor from the Department of History, but this year four junior faculty earned recognition. Making up one-third of the 12 awardees, they are: Amy Marie Cimini, Department of Music; Deborah Isobel Stein, Department of Theatre and Dance; Matthew Werner Vitz, Department of History; and Alena Williams, Department of Visual Arts.
While investigating a potential therapeutic target for the ERK1 and 2 pathway, a widely expressed signaling molecule known to drive cancer growth in one third of patients with colorectal cancer, University of California San Diego School of Medicine researchers found that an alternative pathway immediately emerges when ERK1/2 is halted, thus allowing tumor cell proliferation to continue.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
